Adjuvant (Postoperative) Therapy for Esophageal Cancer

Thoracic Surgery Clinics

Volumn 23, Issue 4, 2013, Pages 525-533

  Ku, Geoffrey Y ^a   Ilson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant; Chemoradiation; Chemotherapy; Esophageal cancer; Gastroesophageal junction cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIRUBICIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GIMERACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; PANITUMUMAB; PLATINUM DERIVATIVE; TEGAFUR; VINDESINE;

ADJUVANT THERAPY; ADVANCED CANCER; ASIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; EUROPE; GASTROINTESTINAL TOXICITY; HUMAN; LOWER ESOPHAGUS SPHINCTER; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT RESPONSE; UNITED STATES;

ADJUVANT; CHEMORADIATION; CHEMOTHERAPY; ESOPHAGEAL CANCER; GASTROESOPHAGEAL JUNCTION CANCER;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84887069500     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2013.07.008     Document Type: Review

References (37)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2013, 63:11-30.
2. Crew K.D., Neugut A.I. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004, 31:450-464.
3. Devesa S.S., Fraumeni J.F. The rising incidence of gastric cardia cancer. JNatl Cancer Inst 1999, 91:747-749.
4. Rubenstein J.H., Taylor J.B. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010, 32:1222-1227.
5. Hampel H., Abraham N.S., El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005, 143:199-211.
6. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
7. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. NEngl J Med 2001, 345:725-730.
8. Fuchs C., Tepper J., Niedzwiecki D., et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. JClin Oncol 2011, 29:4003. [abstract].
9. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. NEngl J Med 2007, 357:1810-1820.
10. Sasako M., Sakuramoto S., Katai H., et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. JClin Oncol 2011, 29:4387-4393.
11. Bang Y.J., Kim Y.W., Yang H.K., et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012, 379:315-321.
12. Ando N., Iizuka T., Kakegawa T., et al. Arandomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. JThorac Cardiovasc Surg 1997, 114:205-209.
13. Ando N., Iizuka T., Ide H., et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. JClin Oncol 2003, 21:4592-4596.
14. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. NEngl J Med 2006, 355:11-20.
15. Ychou M., Boige V., Pignon J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. JClin Oncol 2011, 29:1715-1721.
16. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. NEngl J Med 1998, 339:1979-1984.
17. Allum W.H., Stenning S.P., Bancewicz J., et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. JClin Oncol 2009, 27:5062-5067.
18. Schuhmacher C., Gretschel S., Lordick F., et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. JClin Oncol 2010, 28:5210-5218.
19. Sjoquist K.M., Burmeister B.H., Smithers B.M., et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011, 12:681-692.
20. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. NEngl J Med 1997, 337:161-167.
21. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6:659-668.
22. Tepper J., Krasna M.J., Niedzwiecki D., et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. JClin Oncol 2008, 26:1086-1092.
23. Urba S.G., Orringer M.B., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. JClin Oncol 2001, 19:305-313.
24. van Hagen P., Hulshof M.C., van Lanschot J.J., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. NEngl J Med 2012, 366:2074-2084.
25. Walsh T.N., Noonan N., Hollywood D., et al. Acomparison of multimodal therapy and surgery for esophageal adenocarcinoma. NEngl J Med 1996, 335:462-467.
26. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. JClin Oncol 2005, 23:2310-2317.
27. Stahl M., Wilke H., Lehmann N., Group GOCS, et al. Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus. JClin Oncol 2008, 26:4530. [abstract].
28. Bedenne L., Michel P., Bouche O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. JClin Oncol 2007, 25:1160-1168.
29. Jouve J., Michel P., Mariette C., et al. Outcome of the nonrandomized patients in the FFCD 9102 trial: chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus. JClin Oncol 2008, 26:4555. [abstract].
30. Ilson D., Goodman K., Janjigian Y., et al. Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma. JClin Oncol 2012, 30:67. [abstract].
31. Bendell J.C., Meluch A., Peyton J., et al. Aphase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol 2012, 10:430-437.
32. Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. JClin Oncol 2011, 29:3968-3976.
33. Lordick F., Bodoky G., Chung H., et al. Cetuximab in combination with capecitabine and cisplatin as first-line treatment in advanced gastric cancer: randomized controlled phase III EXPAND study. Ann Oncol 2012, 23:LBA3. [abstract].
34. Waddell T., Chau I., Barbachano Y., et al. Arandomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). JClin Oncol 2012, 30:LBA4000. [abstract].
35. Ferry D., Dutton S., Mansoor W., et al. Phase III multi-centre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib). Ann Oncol 2012, 23:LBA20. [abstract].
36. Crosby T., Hurt C., Falk S., et al. SCOPE 1: a phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. JClin Oncol 2013, 30:LBA3. [abstract].
37. Medical Research Council Oesophageal Cancer Working Group Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002, 359:1727-1733.